

Barcelona, March 7<sup>th</sup> 2017

## **SIGNIFICANT EVENT**

### **Data from Tildrakizumab Clinical Development Program Presented at the 2017 American Academy of Dermatology Meeting**

A

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

Several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, was presented at the 2017 Annual American Academy of Dermatology (AAD) Meeting from March 3-7 in Orlando, Florida.

Data from the pivotal trial was presented that demonstrated the long-term efficacy of tildrakizumab. Patients who achieved PASI 75 response over 28 weeks maintained their response through to 64 weeks.

Tildrakizumab data analyses presented at AAD include:

- Tildrakizumab, a Selective Anti-IL-23 Monoclonal Antibody, Is Effective in Subjects With Chronic Plaque Psoriasis Who Do Not Adequately Respond to Etanercept – Poster 5252
- Efficacy of Tildrakizumab, an Anti-IL23p19 Monoclonal Antibody, Stratified by Prior Exposure to Biologics in a Randomized, Placebo-Controlled Phase 3 Clinical Trial – Poster 5111
- 
- Maintenance of Treatment Response in Chronic Plaque Psoriasis Patients Continuing Treatment or Discontinuing Treatment With Tildrakizumab in a 64-Week, Randomized Controlled, Phase 3 Trial – Poster 4855
- 
- The Effect of Tildrakizumab, a High-Affinity, Selective Anti-IL23p19 Monoclonal Antibody, on Cytochrome P450 Metabolism – Poster 4792

Over 1,800 patients across more than 200 clinical sites participated in the Tildrakizumab Phase-3 pivotal trials (reSURFACE 1 and 2).

Data was presented for the first time demonstrating results through 28 weeks of treatment at the European Academy of Dermatology and Venerology (EADV) Congress in October 2016.

Regulatory filings for Tildrakizumab in the U.S. and Europe are proceeding as planned.

Yours sincerely,

Pablo Divasson del Fraile  
Corporate Comms. & Investor Relations  
[investors@almirall.com](mailto:investors@almirall.com)